Discovery of Retro-1 Analogs Exhibiting Enhanced Anti-vaccinia Virus Activity
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Discovery of Retro-1 Analogs Exhibiting Enhanced Anti-vaccinia Virus Activity

Filetype[PDF-2.79 MB]


  • English
    • Details Supporting Files You May Also Like

    Details:

    • Alternative Title:
      Front Microbiol
    • Personal Author:
    • Description:
      Orthopoxviruses (OPXVs) are an increasing threat to human health due to the growing population of OPXV-naive individuals after the discontinuation of routine smallpox vaccination. Antiviral drugs that are effective as postexposure treatments against variola virus (the causative agent of smallpox) or other OPXVs are critical in the event of an OPXV outbreak or exposure. The only US Food and Drug Administration-approved drug to treat smallpox, Tecovirimat (ST-246), exerts its antiviral effect by inhibiting extracellular virus (EV) formation, thereby preventing cell-cell and long-distance spread. We and others have previously demonstrated that host Golgi-associated retrograde proteins play an important role in monkeypox virus (MPXV) and vaccinia virus (VACV) EV formation. Inhibition of the retrograde pathway by small molecules such as Retro-2 has been shown to decrease VACV infection | and to a lesser extent |. To identify more potent inhibitors of the retrograde pathway, we screened a large panel of compounds containing a benzodiazepine scaffold like that of Retro-1, against VACV infection. We found that a subset of these compounds displayed better anti-VACV activity, causing a reduction in EV particle formation and viral spread compared to Retro-1. PA104 emerged as the most potent analog, inhibiting 90% viral spread at 1.3 μM with a high selectivity index. In addition, PA104 strongly inhibited two distinct ST-246-resistant viruses, demonstrating its potential benefit for use in combination therapy with ST-246. These data and further characterizations of the specific protein targets and | efficacy of PA104 may have important implications for the design of effective antivirals against OPXV.
    • Subject:
    • Source:
      Front Microbiol. 2020; 11
    • Pubmed ID:
      32390964
    • Pubmed Central ID:
      PMC7190985
    • Document Type:
      Journal Article
    • Collection(s):
      CDC Public Access
    • Main Document Checksum:
    • File Type:

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov